Glutamate is the major excitatory neurotransmitter in the mammalian brain and acts at the same time as one of the most powerful neurotoxins. In order to ensure a continuous communication between nerve cells, glutamate transporters are crucial for both the efficient removal of transmitter and the buffering of glutamate in the synaptic cleft during synaptic transmission. The buffering of glutamate subsequently influences the activation of different receptor classes in a spatio-temporal manner. In this context the rapid translocation of glutamate transporters between plasma membrane and intracellular compartments (membrane trafficking) is an interesting regulatory aspect for changes in cell surface localization. This highly dynamic mechanism is well-established for different glutamate receptor classes and associated with synaptic plasticity. In this thesis membrane trafficking of glial and neuronal glutamate transporters and its underlying regulative endo- and exocytic mechanisms were investigated in detail. Thereby a novel tyrosine-based adaptor protein complex 2 (AP2) binding motif - Y V N G G F - in the cytoplasmic C-terminus of glutamate transporter subtype EAAC1 was identified. The interaction between AP2 and its binding motif facilitates clathrin-mediated endocytosis of EAAC1, which is constitutively recycled between plasma membrane and endosomal structures under basal conditions. Additionally the activity of tyrosine kinases could be linked to the plasma membrane localization of EAAC1, suggesting the regulation of AP2-EAAC1 interaction by phosphorylation of the tyrosine residue within the identified binding motif. Furthermore it could be shown that cholesterol directly influences both endocytosis of EAAC1 and transporter functionality. Altogether the data offers new insights into modulatory mechanisms underlying glutamatergic neurotransmission and elucidation in regards to diseases of the central nervous system associated with glutamate toxicity.

yes / Abstract Recent evidence suggests that the predominant astrocyte glutamate transporter, GLT-1/ Excitatory Amino Acid Transporter 2 (EAAT2) is associated with mitochondria. We used primary cultures of mouse astrocytes to assess co-localization of GLT-1 with mitochondria, and tested whether the interaction was dependent on neurons, actin polymerization or the kinesin adaptor, TRAK2. Mouse primary astrocytes were transfected with constructs expressing V5-tagged GLT-1, pDsRed1-Mito with and without dominant negative TRAK2. Astrocytes were visualized using confocal microscopy and co-localization was quantified using Volocity software. Image analysis of confocal z-stacks revealed no co-localization between mitochondria and GLT-1 in pure astrocyte cultures. Co-culture of astrocytes with primary mouse cortical neurons revealed more mitochondria in processes and a positive correlation between mitochondria and GLT-1. This co-localization was not further enhanced after neuronal depolarization induced by 1 h treatment with 15 mM K+. In pure astrocytes, a rho kinase inhibitor, Y27632 caused the distribution of mitochondria to astrocyte processes without enhancing GLT-1/mitochondrial co-localization, however, in co-cultures, Y27632 abolished mitochondrial: GLT-1 co-localization. Disrupting potential mitochondrial: kinesin interactions using dominant negative TRAK2 did not alter GLT-1 distribution or GLT-1: mitochondrial co-localization. We conclude that the association between GLT-1 and mitochondria is modest, is driven by synaptic activity and dependent on polymerized actin filaments. Mitochondria have limited co-localization with the glutamate transporter GLT-1 in primary astrocytes in culture. Few mitochondria are in the fine processes where GLT-1 is abundant. It is necessary to culture astrocytes with neurones to drive a significant level of co-localization, but co-localization is not further altered by depolarization, manipulating sodium ion gradients or Na/K ATPase activity.

Doctor of Philosophy (Medicine) / Glutamate transporters play a role in removing extracellular excitatory neurotransmitter, L-glutamate into the cells. The rate of the uptake depends on the density of the transporters at the membrane. Some studies claimed that glutamate transporters could transit between the cytoplasm and the membrane on a time-scale of minutes. The present study examined the distribution of glutamate transporter GLAST predominantly expressed in rat cortical cultured astrocytes between the membrane and the cytoplasm by using deconvolution microscopy and then analyzing the images. The regulation of the distribution of GLAST was studied in the presence of glutamate transporter substrate (D-aspartate), purinergic receptor activators (α,β-methylene ATP, adenosine), neuroleptic drugs (clozapine, haloperidol), ammonia (hyperammonia) and Na+/K+-ATPase inhibitors (ouabain, digoxin and FCCP). It was demonstrated that the translocation of GLAST towards the plasma membrane was induced by D-aspartate, α,β-methylene ATP, adenosine, clozapine and ammonia (at 100 μM and very high concentrations of 10 mM). However, the inhibition of Na+/K+-ATPase activity had an opposite effect, resulting in redistribution of GLAST away from the membrane. It has previously been claimed that the membrane-cytoplasm trafficking of GLAST was regulated by phosphorylation catalysed by protein kinase C delta (PKC-delta). Involvement of this mechanism has, however, been put to doubt when rottlerin, a PKC-delta inhibitor, used to test the hypothesis showed to inhibit Na+/K+-ATPase-mediated uptake of Rb+, suggesting that rottlerin influenced the activity of Na+/K+-ATPase. As Na+/K+-ATPase converts ATP to energy and pumps Na+, K+ ions, thus helping to maintain normal electrochemical and ionic gradients across the cell membrane. Its inhibition also reduced D-aspartate transport and could impact on the cytoplasm-to-membrane traffic of GLAST molecules. Furthermore, rottlerin decreased the activity of Na+/K+-ATPase by acting as a mitochondrial inhibitor. The present study has focused on the inhibition of Na+/K+-ATPase activity by rottlerin, ouabain and digoxin in homogenates prepared from rat kidney and cultured astrocytes. The activity of Na+/K+-ATPase was measured by the absorption of inorganic phosphate product generated from the hydrolysis of ATP and the fluorescent transition of the dye RH421 induced by the movement of Na+/K+-ATPase. This approach has a potential to test whether the rottlerin effect on Na+/K+-ATPase is a direct inhibition of the enzyme activity. Rottlerin has been found to block the activity of Na+/K+-ATPase in a dose-dependent manner in both rat kidney and astrocyte homogenates. Therefore, rottlerin inhibited the activity of Na+/K+-ATPase directly in a cell-free preparation, thus strongly indicating that the effect was direct on the enzyme. In parallel experiments, ouabain and digoxin produced similar inhibitions of Na+/K+-ATPase activity in rat kidney while digoxin blocked the activity of Na+/K+-ATPase to a greater extent than ouabain in rat cortical cultured astrocytes. In a separate set of experiments, Na+/K+-ATPase in the astrocytic membrane was found to be unsaturated in E1(Na+)3 conformation in the presence of Na+ ions and this could explain the differences between the effects of digoxin and ouabain on the activity of Na+/K+-ATPase in rat astrocytes. In addition, it was found that at low concentrations of rottlerin, the activity of Na+/K+-ATPase was increased rather than inhibited. This effect was further investigated by studying rottlerin interactions with membrane lipids. The activity of Na+/K+-ATPase has been reported to be regulated by membrane lipids. The enzyme activity can be enhanced by increasing fluidity of the lipid membrane. I have, therefore, proposed that rottlerin binds to the membrane lipids and the effects of rottlerin on Na+/K+-ATPase are mediated by changes in the properties (fluidity) of the membrane. The hypothesis was tested by comparing rottlerin and a detergent, DOC (sodium deoxycholate), for their binding to the lipids by using a DMPC (1,2-Dimyristoyl-sn-Glycero-3-Phosphocholine) monolayer technique. DOC has been shown to both increase and inhibit activity of Na+/K+-ATPase in a manner similar to that displayed by rottlerin. The effects of rottlerin and DOC on the DMPC monolayers were studied by measuring the surface pressure of DMPC monolayers and surface area per DMPC molecule. I established that both rottlerin and DOC decreased the surface pressure of DMPC monolayers and increased the surface area per DMPC molecule. This indicates that both rottlerin and DOC penetrated into the DMPC monolayers. If rottlerin can interact with the lipids, changes in fluidity of the lipid membrane cannot be ruled out and should be considered as a possible factor contributing to the effects of rottlerin on the activity of Na+/K+-ATPase. Overall, the study demonstrates that rottlerin is not only a PKC-delta inhibitor but can have additional effects, both on the enzyme activities (Na+/K+-ATPase) and/or on lipid-containing biological structures such as membranes. The findings have implication not only for studies where rottlerin was used as a supposedly specific PKC-delta inhibitor but also for mechanisms of its toxicity.

Doctor of Philosophy (Medicine) / Glutamate transporters play a role in removing extracellular excitatory neurotransmitter, L-glutamate into the cells. The rate of the uptake depends on the density of the transporters at the membrane. Some studies claimed that glutamate transporters could transit between the cytoplasm and the membrane on a time-scale of minutes. The present study examined the distribution of glutamate transporter GLAST predominantly expressed in rat cortical cultured astrocytes between the membrane and the cytoplasm by using deconvolution microscopy and then analyzing the images. The regulation of the distribution of GLAST was studied in the presence of glutamate transporter substrate (D-aspartate), purinergic receptor activators (α,β-methylene ATP, adenosine), neuroleptic drugs (clozapine, haloperidol), ammonia (hyperammonia) and Na+/K+-ATPase inhibitors (ouabain, digoxin and FCCP). It was demonstrated that the translocation of GLAST towards the plasma membrane was induced by D-aspartate, α,β-methylene ATP, adenosine, clozapine and ammonia (at 100 μM and very high concentrations of 10 mM). However, the inhibition of Na+/K+-ATPase activity had an opposite effect, resulting in redistribution of GLAST away from the membrane. It has previously been claimed that the membrane-cytoplasm trafficking of GLAST was regulated by phosphorylation catalysed by protein kinase C delta (PKC-delta). Involvement of this mechanism has, however, been put to doubt when rottlerin, a PKC-delta inhibitor, used to test the hypothesis showed to inhibit Na+/K+-ATPase-mediated uptake of Rb+, suggesting that rottlerin influenced the activity of Na+/K+-ATPase. As Na+/K+-ATPase converts ATP to energy and pumps Na+, K+ ions, thus helping to maintain normal electrochemical and ionic gradients across the cell membrane. Its inhibition also reduced D-aspartate transport and could impact on the cytoplasm-to-membrane traffic of GLAST molecules. Furthermore, rottlerin decreased the activity of Na+/K+-ATPase by acting as a mitochondrial inhibitor. The present study has focused on the inhibition of Na+/K+-ATPase activity by rottlerin, ouabain and digoxin in homogenates prepared from rat kidney and cultured astrocytes. The activity of Na+/K+-ATPase was measured by the absorption of inorganic phosphate product generated from the hydrolysis of ATP and the fluorescent transition of the dye RH421 induced by the movement of Na+/K+-ATPase. This approach has a potential to test whether the rottlerin effect on Na+/K+-ATPase is a direct inhibition of the enzyme activity. Rottlerin has been found to block the activity of Na+/K+-ATPase in a dose-dependent manner in both rat kidney and astrocyte homogenates. Therefore, rottlerin inhibited the activity of Na+/K+-ATPase directly in a cell-free preparation, thus strongly indicating that the effect was direct on the enzyme. In parallel experiments, ouabain and digoxin produced similar inhibitions of Na+/K+-ATPase activity in rat kidney while digoxin blocked the activity of Na+/K+-ATPase to a greater extent than ouabain in rat cortical cultured astrocytes. In a separate set of experiments, Na+/K+-ATPase in the astrocytic membrane was found to be unsaturated in E1(Na+)3 conformation in the presence of Na+ ions and this could explain the differences between the effects of digoxin and ouabain on the activity of Na+/K+-ATPase in rat astrocytes. In addition, it was found that at low concentrations of rottlerin, the activity of Na+/K+-ATPase was increased rather than inhibited. This effect was further investigated by studying rottlerin interactions with membrane lipids. The activity of Na+/K+-ATPase has been reported to be regulated by membrane lipids. The enzyme activity can be enhanced by increasing fluidity of the lipid membrane. I have, therefore, proposed that rottlerin binds to the membrane lipids and the effects of rottlerin on Na+/K+-ATPase are mediated by changes in the properties (fluidity) of the membrane. The hypothesis was tested by comparing rottlerin and a detergent, DOC (sodium deoxycholate), for their binding to the lipids by using a DMPC (1,2-Dimyristoyl-sn-Glycero-3-Phosphocholine) monolayer technique. DOC has been shown to both increase and inhibit activity of Na+/K+-ATPase in a manner similar to that displayed by rottlerin. The effects of rottlerin and DOC on the DMPC monolayers were studied by measuring the surface pressure of DMPC monolayers and surface area per DMPC molecule. I established that both rottlerin and DOC decreased the surface pressure of DMPC monolayers and increased the surface area per DMPC molecule. This indicates that both rottlerin and DOC penetrated into the DMPC monolayers. If rottlerin can interact with the lipids, changes in fluidity of the lipid membrane cannot be ruled out and should be considered as a possible factor contributing to the effects of rottlerin on the activity of Na+/K+-ATPase. Overall, the study demonstrates that rottlerin is not only a PKC-delta inhibitor but can have additional effects, both on the enzyme activities (Na+/K+-ATPase) and/or on lipid-containing biological structures such as membranes. The findings have implication not only for studies where rottlerin was used as a supposedly specific PKC-delta inhibitor but also for mechanisms of its toxicity.

No description available.

No description available.

No description available.

Glutamat ist der wichtigste exzitatorische Neurotransmitter im Zentralnervensystem der Säugetiere. Die präzise Kontrolle des extrazellulären Glutamatspiegels ist für eine normale synaptische Transmission wichtig und erforderlich, um die Neurone vor Exzitotoxizität zu schützen. Im Gehirn sorgen vor allem verschiedene hochaffine Na+-abhängige Glutamattransporter für diese Kontrolle. In der vorliegenden Arbeit wurde deshalb untersucht, welchen Einfluß die Inhibition der Glutamattransporter auf die exzitatorische synaptische Transmission in Schicht III, einer Region in der bei Alzheimer-Demenz, Schizophrenie und Epilepsie häufig Zellschädigungen und Zellverluste beobachtet werden, und Schicht V des medialen entorhinalen Kortex (mEC) hat. Extrazelluläre Messungen in den Schichten III und V der Ratte zeigten, daß die verwendeten Transport-Inhibitoren signifikant die negativen Feldpotentialkomponenten beider Schichten reduzierten. Schichtspezifische Unterschiede konnten dabei nicht festgestellt werden, was auf eine ähnliche Glutamatregulation in beiden Schichten schließen läßt. Für die anschließenden intrazellulären und patch-clamp Messungen wurden aus diesem Grund nur noch Neurone der Schicht III untersucht. Beide Transport-Inhibitoren (L-trans-2,4-PDC und DL-TBOA) reduzierten die Amplituden der pharmakologisch isolierbaren EPSPs/EPSCs ohne die Kinetik zu beeinflussen. Diese reduzierende Wirkung konnte durch trans-(±)-ACPD, einen Agonisten der Gruppe I und II metabotropen Glutamatrezeptoren (mGluRs), nachgeahmt werden. Die Vorinkubation der Hirnschnitte mit dem unspezifischen Gruppe I und II mGluR-Antagonisten MCPG verhinderte die durch trans-(±)-ACPD hervorgerufene Amplitudenreduktion und auch den reduzierenden Effekt der beiden Transport-Inhibitoren. In nachfolgenden Experimenten mit dem spezifischen Gruppe II mGluR-Antagonisten EGLU konnte dieser zwar die durch L-trans-2,4-PDC hervorgerufene Wirkung verhindern, nicht aber den durch DL-TBOA vermittelten Effekt, was auf eine Aktivierung von Gruppe I mGluRs hinweist. Zusätzlich führte die Applikation von DL-TBOA zu einer signifikanten Veränderung des Doppelpuls-Index, was auf einen präsynaptischen Wirkmechanismus hinweist. Die Applikation von L-trans-2,4-PDC hingegen hatte keinen Effekt auf den Doppelpuls-Index. Die Ergebnisse der vorliegenden Arbeit sprechen dafür, daß beide Transport-Inhibitoren die erregende synaptische Transmission über eine Aktivierung präsynaptischer metabotroper Glutamatrezeptoren der Gruppen I und II hemmen. Dabei konnte festgestellt werden, daß diese Hemmung unter Applikation von DL-TBOA die präsynaptische Transmitterausschüttung über einen negativen Rückkopplungsmechanismus durch Aktivierung von Gruppe I mGluRs vermindert, während L-trans-2,4-PDC seine Wirkung vor allem über eine Aktivierung der Gruppe II vermittelt. Dabei kann davon ausgegangen werden, daß L-trans-2,4-PDC in der benutzten Konzentration die mGluRs der Gruppe II direkt aktivieren kann und der Effekt nicht nur präsynaptisch vermittelt wird. / Glutamate is the primary excitatory neurotransmitter in the mammalian central nervous system. The precise control of extracellular glutamate is crucial for the maintenance of normal synaptic transmission and the prevention of excitotoxicity. High-affinity glutamate transporters ensure termination of glutamatergic neurotransmission and keep the synaptic glutamate concentration below excitotoxic levels. In layer III, a region that is especially prone to cell damage in Alzheimer's disease, schizophrenia and epilepsy, and layer V of the medial entorhinal cortex (mEC) effects of blocking glutamate uptake on excitatory synaptic transmission were studied. Extracellular recordings in rat brain slices revealed that application of glutamate uptake inhibitors significantly reduced stimulus-induced negative field potentials in both, layer III and V of the mEC. This effect showed no significant differences in both layers suggesting a similar glutamate regulation in layer III and V. Therefore, only layer III neurons of the mEC were used for the subsequent intracellular and patch-clamp recordings. Two competitive glutamate transporter antagonists, DL-TBOA and L-trans-2,4-PDC, reduced the amplitude of pharmacologically isolated EPSPs/EPSCs without changing the time course of the events. This effect was mimicked by trans-(±)-ACPD, an agonist of group I and II metabotropic glutamate receptors (mGluRs). The competitive group I and II mGluR antagonist MCPG blocked the depression of the EPSC amplitude induced by trans-(±)-ACPD and also masked the effect of either DL-TBOA or L-trans-2,4-PDC. Furthermore, EGLU, which selectively antagonizes group II mGluRs, masked the effect of L-trans-2,4-PDC but not that of DL-TBOA, indicating an involvement of group I mGluRs in the latter case. Finally, DL-TBOA significantly enhanced the paired-pulse index, suggesting a presynaptic mechanism for the depression of EPSP/EPSC amplitude, whereas application of L-trans-2,4-PDC had no significant effect on the paired-pulse behaviour. The present study shows that both transport inhibitors depress pharmacologically isolated EPSPs/EPSCs in layer III neurons of the mEC in combined entorhinal-hippocampal slices. This effect seems to be mediated via activation of different groups of mGluRs. The results suggest that DL-TBOA causes a negative feedback on glutamate release via indirect activation of presynaptic group I mGluRs, possibly due to an accumulation of glutamate, whereas application of L-trans-2,4-PDC most likely leads to an activation of presynaptic group II mGluRs reducing Ca2+-independent release. The latter might be due to a direct action of L-trans-2,4-PDC at these receptors. The present data suggest that blockade of glutamate transport in the mEC does not lead to an excessive accumulation of glutamate because of a counteractive autoinhibiting mechanism.

Le glutamate est accumulé dans des vésicules synaptiques par des transporteurs vésiculaires du glutamate appelés VGLUT1-3. VGLUT1 et VGLUT2 sont utilisés par les neurones glutamatergiques «classiques» corticaux et sous-corticaux. VGLUT3 est présent dans des sous-populations de neurones utilisant d’autres neurotransmetteurs que le glutamate. Dans la cochlée, VGLUT3 permet la transmission glutamatergique entre les cellules ciliées internes et les neurones du nerf auditif. Le travail mené par l’équipe du Pr Puel a permis de découvrir l’implication de VGLUT3 dans une pathologie héréditaire de l’audition chez l’Homme. Une mutation p.A211V du gène codant VGLUT3 humain est responsable d’une surdité progressive à transmission autosomique. Il s’agit de la première mutation d’un VGLUT associé à une pathologie humaine. Mon travail de thèse a consisté à caractériser l’impact de cette mutation sur le SNC d’une lignée de souris exprimant cette mutation. Nous avons observé que cette mutation avait des effets complexes sur VGLUT3. La mutation p.A211V entraine une baisse marquée de l’expression de VGLUT3 dans les terminaisons nerveuses qui semble liée à une dégradation accélérée de VGLUT3. 20% d’expression résiduelle de VGLUT3 suffisent à assurer la majeure partie des fonctions du transporteur. L’activité de VGLUT3 ne semble donc pas être linéairement corrélée à son expression. De plus, la réduction de VGLUT3 au niveau des synapses semble s’accompagner d’une réduction du nombre de vésicules VGLUT3-positives et d’une réduction du nombre de copies de VGLUT3 par vésicule. Dans l’ensemble, mon travail de thèse a permis d’acquérir une meilleure connaissance de la régulation de VGLUT3. / Glutamate is the major excitatory neurotransmitter in the Central Nervous System (CNS) and is accumulated into synaptic vesicles by proton-dependent transporters named VGLUT1-3. VGLUT1 and VGLUT2-positive neurons are respectively found in cortical and subcortical glutamatergic neurons. In contrast, VGLUT3 is localized in a small population of neurons using other neurotransmitter than glutamate i.e.: cholinergic interneurons in the striatum, subpopulation of GABAergic interneurons in the hippocampus and cortex and serotoninergic neurons. Furthermore, VGLUT3 is also expressed by sensory inner hear cells (IHCs).In the cochlea, VGLUT3 accumulates glutamate into synaptic vesicles of the IHCs. A mutation of the gene that encodes VGLUT3 is responsible for a progressive, high-frequency deafness. It is the first mutation of a VGLUT that was demonstrated to be responsible for a human pathology.We investigated the effects of the p.A211V mutation on VGLUT3 in the CNS of a mouse line expressing this mutation. We observed that this mutation had complex effects on VGLUT3. The p.A211V mutation causes a 80% decrease of VGLUT3 in nerve endings. 20% residual expression of VGLUT3 is sufficient to fulfill most part of its functions. Contrary to prevailing views, VGLUT3 global activity is not linearly correlated to VGLUT3 quantity. Futhermore, VGLUT3 reduction seems to be associated with a diminution of VGLUT3-positive vesicles accompanied by an homogenous reduction of VGLUT3 copy number per vesicle.Overall, my thesis allowed to acquire a better understanding of the regulation of VGLUT3. This work will deepen our understanding of the involvement of VGLUTs in various pathologies.

Avant sa libération, le glutamate est accumulé dans des vésicules synaptiques par trois transporteurs vésiculaires (VGLUT1-3). Les cellules ciliées internes (CCI) de la cochlée n'expriment que VGLUT3. Pour étudier son rôle dans la physiologie cochléaire, nous avons utilisé une lignée de souris dont le gène Slc17a8, qui code pour VGLUT3, a été invalidé par recombinaison homologue. Les mutants ne présentaient pas de réponse nerveuse à une stimulation sonore. Les mécanismes d'exocytose des CCI étaient normaux et leurs synapses normales en microscopie électronique. Des immunoblots montraient que le transporteur membranaire du glutamate GLAST, ainsi que les sous-unités GLUR2 et NR1 des récepteurs AMPA et NMDA étaient toujours exprimées. Enfin, des potentiels auditifs du tronc cérébral étaient enregistrés après une stimulation électrique au niveau de la fenêtre ronde. Toutefois, nos résultats indiquent des diminutions de ~50% des synapses afférentes et de ~40% des neurones auditifs primaires ainsi qu'une réduction importante des terminaisons efférentes latérales sous les CCI.SLC17A8 est responsable de la surdité de perception non syndromique dominante DFNA25. Nous avons identifié une mutation dans l'exon 5 conduisant au remplacement de l'Alanine211 en Valine. Cette Alanine est conservée dans les VGLUT3 de différentes espèces ainsi que dans les VGLUT1-3 humains, suggérant un rôle fonctionnel important pour cet acide aminé. Nous avons caractérisé les propriétés biochimiques de la mutation A211V en culture de cellules. Le transporteur muté était correctement adressé aux boutons présynaptiques. Cependant, la mutation pA211V entraîne un défaut d'expression important en partie expliqué par le fait que le codon codant la valine est un codon rare. De plus, les études du transport de glutamate ont montré que la forme mutée est hyperactive par rapport à la forme native. L'ensemble de ces résultats montre que la mutation entraine un phénotype cellulaire complexe. / Before its release, glutamate is accumulated into synaptic vesicles by three vesicular glutamate transporters (VGLUT1-3). Only VGLUT3 is expressed in the inner hair cells (IHCs) of the cochlea. To study its role in the hearing physiology, we used a mouse in which the Slc17a8 gene, which encodes VGLUT3, has been null-mutated. In this VGLUT3-/- mouse, no auditory nerve response to acoustic stimuli could be recorded. All the others cochlear potentials were normal. The genetic deletion of Slc17a8 in mice resulted in a profound deafness, without altering the IHCs synapse morphology and the synaptic vesicles turnover. Using western blot, we then observed that the glutamate-aspartate transporter GLAST and the GLUR2 and NR1 subunits of AMPA and NMDA receptors were always expressed. Finally, auditory brainstem responses could be elicited by electrical stimuli on the round window. However, VGLUT3-/- IHCs presented a ~50% loss of IHCs synapses and a ~40% loss of primary auditory neurons. The number of lateral olivocochlear synapses with primary auditory neurons dendrites was strongly reduced.The SLC17A8 gene is responsible for DFNA25, an autosomal dominant progressive, high-frequency nonsyndromic deafness. We identified a heterozygous non-synonymous missense mutation in exon 5, leading to the amino acid change p.A211V. The A211 residue is conserved in VGLUT3 across species and in all the human VGLUT subtypes (VGLUT1-3), suggesting an important functional role. We characterized the biochemical properties of the A211V mutation in cell culture. Our results suggest that the mutated VGLUT3 was correctly addressed at the presynaptic boutons. However, the pA211V mutation induced an expression decrease because the valine codon is a rare codon. Moreover, the glutamate uptake is increased with the mutated VGLUT3. All these results shows that this mutation involves a complex cellular phenotype.